Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE)

Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE)

Introduction

Limbic Predominant Age Related Tdp 43 Encephalopathy (Late) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Limbic-Predominant Age-Related [TDP-43](/proteins/tdp-43) Encephalopathy (LATE) is a recently recognized neurodegenerative condition characterized by [TDP-43](/proteins/tdp-43) protein pathology predominantly affecting the limbic system, particularly in older adults. First described in 2019, LATE represents an underappreciated cause of dementia that often mimics Alzheimer's Disease but has distinct pathological features. [@role]

Limbic-predominant age-related [TDP-43](/mechanisms/tdp-43-proteinopathy) encephalopathy (LATE) is a recently recognized neurodegenerative disease characterized by the accumulation of misfolded [TDP-43](/proteins/tdp-43) protein in the limbic system, particularly the [amygdala](/brain-regions/amygdala) and [hippocampus](/brain-regions/hippocampus). First formally defined by a consensus working group in 2019, LATE produces a clinical syndrome that closely mimics [Alzheimer's disease](/diseases/alzheimers-disease) but has distinct molecular pathology.[@progression] [@elucidation]

Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE)

Introduction

Limbic Predominant Age Related Tdp 43 Encephalopathy (Late) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Limbic-Predominant Age-Related [TDP-43](/proteins/tdp-43) Encephalopathy (LATE) is a recently recognized neurodegenerative condition characterized by [TDP-43](/proteins/tdp-43) protein pathology predominantly affecting the limbic system, particularly in older adults. First described in 2019, LATE represents an underappreciated cause of dementia that often mimics Alzheimer's Disease but has distinct pathological features. [@role]

Limbic-predominant age-related [TDP-43](/mechanisms/tdp-43-proteinopathy) encephalopathy (LATE) is a recently recognized neurodegenerative disease characterized by the accumulation of misfolded [TDP-43](/proteins/tdp-43) protein in the limbic system, particularly the [amygdala](/brain-regions/amygdala) and [hippocampus](/brain-regions/hippocampus). First formally defined by a consensus working group in 2019, LATE produces a clinical syndrome that closely mimics [Alzheimer's disease](/diseases/alzheimers-disease) but has distinct molecular pathology.[@progression] [@elucidation]

LATE is among the most common causes of dementia in older adults, affecting approximately 20–50% of individuals over age 80 at autopsy. The condition frequently co-occurs with Alzheimer's Disease neuropathologic change, and when both pathologies are present, cognitive decline is more severe than with either alone.[@role] [@trimubqlnp]

Epidemiology

Prevalence

LATE neuropathologic change (LATE-NC) is remarkably prevalent in the aging brain: [@tdp]

• Autopsy studies detect LATE-NC in approximately 25% of brains from community-based cohorts of individuals over age 80[@progression]
• An estimated 15–20% of clinically diagnosed Alzheimer's Disease cases in the oldest old (age 80+) may actually be attributable to LATE[@role]
• Prevalence increases sharply with age: rare before age 70, increasingly common after age 80, and very common after age 90
• In the oldest old (90+), LATE-NC may be more prevalent than Alzheimer's-type pathology alone

Risk Factors

• Age: The strongest risk factor; LATE is overwhelmingly a disease of advanced age
• Female sex: Women appear to be at modestly higher risk
• Genetic factors: Variants in [TMEM106B](/proteins/tmem106b-protein), [GRN](/proteins/grn-protein) (encoding [progranulin](/entities/grn), ABCC9, KCNMB2, and [APOE](/proteins/apoe-protein), a nuclear RNA-binding protein that normally regulates mRNA splicing, stability, and transport. In LATE:

This TDP-43 pathology is shared with [ALS](/diseases/amyotrophic-lateral-sclerosis) and [frontotemporal lobar degeneration](/diseases/frontotemporal-lobar-degeneration) (FTLD-TDP), but in LATE, the distribution is distinctly limbic-predominant rather than involving motor [neurons](/entities/neurons) or frontotemporal [cortex](/brain-regions/cortex).[@tdp] [^6]

Staging System (LATE-NC Stages)

LATE neuropathologic change follows a stereotypical spatial progression:[@progression] [^7]

| Stage | Region Affected | Description | [^8]
|-------|----------------|-------------| [^9]
| Stage 0 | None | No TDP-43 cytoplasmic inclusions detected | [^10]
| Stage 1 | [amygdala](/brain-regions/amygdala) | TDP-43 inclusions restricted to the amygdala |
| Stage 2 | [hippocampus](/brain-regions/hippocampus) | Spread to hippocampus and entorhinal [cortex](/brain-regions/cortex) |
| Stage 3 | Neocortex | Extension to middle frontal gyrus and additional neocortical regions |

Higher stages correlate with greater cognitive impairment. Stage 1 may be asymptomatic, while stages 2 and 3 are associated with progressive memory loss and clinical dementia.

Hippocampal Sclerosis

A frequent companion pathology in LATE is hippocampal sclerosis of aging (HS-Aging), characterized by:

• Severe neuronal loss in the CA1 sector and subiculum of the [hippocampus](/brain-regions/hippocampus)
• Reactive gliosis with [astrocytes](/cell-types/astrocytes) and [microglial activation
• Disproportionate hippocampal atrophy visible on MRI

Relationship to Other Proteinopathies

LATE-NC frequently co-occurs with other neuropathologies:

• Alzheimer's Disease neuropathologic change (ADNC): [amyloid-beta](/proteins/amyloid-beta) plaques and tau] neurofibrillary tangles. Combined LATE + AD leads to worse cognitive outcomes than either alone
• Age-related [tau](/proteins/tau) astrogliopathy (ARTAG): [Tau](/proteins/tau) deposits in [astrocytes](/cell-types/astrocytes), common in aging
• Cerebrovascular disease: Arteriolosclerosis, microinfarcts, and white matter changes
• Lewy body pathology: [alpha-synuclein/proteins/alpha deposits may also co-occur

Genetics

Established Risk Genes

Several genetic loci have been replicated as risk factors for LATE-NC:[@elucidation]

| Gene | Variant | Effect | Notes |
|------|---------|--------|-------|
| TMEM106B | rs1990622 | Risk/protection | Also associated with FTLD-TDP; modulates TDP-43 aggregation |
| GRN | rs5848 | Risk | Encodes [progranulin](/entities/grn); complete GRN loss causes FTLD; partial loss contributes to LATE |
| [APOE | ε4 allele | Risk | Shared risk factor with [Alzheimer's disease](/diseases/alzheimers-disease) |
| SORL1 | Multiple variants | Risk | Also associated with Alzheimer's Disease |
| ABCC9 | rs1914361, rs701478 | Risk | Encodes SUR2 potassium channel subunit; linked to vascular pathology |
| KCNMB2 | Multiple variants | Risk | Encodes potassium channel subunit |

Genetic Overlap with Other TDP-43 Diseases

The shared genetic architecture between LATE and FTLD-TDP (via GRN and TMEM106B) and with [Alzheimer's disease](/diseases/alzheimers-disease) (via [APOE](/proteins/apoe-protein) and SORL1) suggests converging biological pathways despite distinct clinical presentations.[^7]

Clinical Presentation

Symptoms

LATE presents as a slowly progressive amnestic dementia syndrome that is clinically indistinguishable from Alzheimer's Disease during life:

• Memory impairment: The predominant feature; similar to early [Alzheimer's disease](/diseases/alzheimers-disease)
• Slower progression: Generally progresses more slowly and is milder than typical Alzheimer's
• Later onset: Typically manifests after age 80, later than typical Alzheimer's Disease
• Preserved executive function: Executive and visuospatial abilities may be relatively spared in early stages
• Behavioral changes: Can include apathy, depression, and personality changes in advanced stages

Differentiation from Alzheimer's Disease

| Feature | LATE | [Alzheimer's disease](/diseases/alzheimers-disease) |
|---------|------|------|
| Typical onset age | >80 years | 60–80 years (late-onset) |
| Core protein | [TDP-43](/proteins/tdp-43) | [amyloid-beta](/proteins/amyloid-beta) and tau] |
| Brain regions | Limbic (amygdala, hippocampus) | Widespread cortical |
| [amyloid PET](/entities/amyloid-pet) | Negative (pure LATE) | Positive |
| Progression rate | Slower | Moderate to rapid |
| Genetic risk | TMEM106B, GRN, [APOE](/proteins/apoe-protein) | [APOE](/genes/apoe), [APP](/entities/app-protein), [PSEN1](/proteins/psen1-protein), [PSEN2](/proteins/psen2-protein) |

Diagnosis

Current Limitations

LATE can only be definitively diagnosed at autopsy through neuropathological examination for [TDP-43](/proteins/tdp-43) inclusions. During life, a clinical diagnosis of "probable LATE" is increasingly feasible using a combination of approaches.[^8]

Proposed Clinical Criteria (2025)

In 2025, the first clinical diagnostic criteria for LATE were published:[^8]

• Probable LATE: Amnestic dementia syndrome in an individual over 80 years with negative amyloid biomarkers (amyloid PET or CSF amyloid
• Possible LATE: Amnestic dementia syndrome with amyloid biomarkers unavailable, or when amyloid is present (since LATE and Alzheimer's frequently co-occur)

Biomarkers Under Investigation

• MRI: Limbic-predominant atrophy pattern, particularly hippocampal atrophy disproportionate to overall cortical atrophy
• PET imaging: Amyloid-negative status in the setting of dementia is suggestive
• Blood-based biomarkers: Plasma [NfL](/proteins/nfl-protein)) ([neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain) elevation; absence of [amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) biomarker signatures
• TDP-43-specific biomarkers: Under development but not yet clinically available

Neuroimaging Features

• Hippocampal atrophy: Often severe; may include frank hippocampal sclerosis
• Medial temporal atrophy: Prominent [amygdala](/brain-regions/amygdala) and [entorhinal cortex](/brain-regions/entorhinal-cortex) atrophy
• Relative cortical sparing: Less global cortical atrophy than in typical Alzheimer's
• FDG-PET: Limbic-predominant hypometabolism

Treatment and Management

Current Status

There are no approved treatments specifically targeting LATE. Current management is supportive:

• Symptomatic treatment: [Cholinesterase inhibitors](/entities/cholinesterase-inhibitors) and memantine (as used in Alzheimer's) may provide modest benefit, though their efficacy specifically in LATE has not been established
• Behavioral management: Non-pharmacological approaches for dementia symptoms
• Caregiver support: Similar to other dementia care
• Comorbidity management: Cardiovascular risk reduction given frequent co-occurrence with cerebrovascular disease

Therapeutic Implications

The recognition of LATE has important implications for Alzheimer's therapeutics:

• Clinical trial design: Anti-amyloid therapies (e.g., [lecanemab](/therapeutics/lecanemab), donanemab) are unlikely to benefit patients with pure LATE
• Diagnostic screening: LATE may explain why some "Alzheimer's" patients do not respond to amyloid-targeted therapies
• New drug targets: TDP-43 aggregation, GRN/progranulin pathways, and TMEM106B may represent therapeutic targets

Research Directions

• Development of TDP-43-specific PET tracers for in vivo diagnosis
• Blood-based biomarkers to distinguish LATE from Alzheimer's Disease
• Clinical trials specifically targeting TDP-43 pathology
• Understanding the biology of selective vulnerability of limbic structures
• Investigation of the ABCC9/SUR2 pathway as a potential drug target[@elucidation]

Current Research

Key Milestones

• 2019: Consensus working group formally defined LATE as a distinct disease entity (Nelson et al., Brain)[@progression]
• 2022: Updated LATE-NC staging guidelines published (Acta Neuropathologica)[^9]
• 2024: Population-based study in the oldest old confirmed LATE prevalence rates[^10]
• 2025: First clinical diagnostic criteria for probable/possible LATE published (Wolk et al., Alzheimer's & Dementia)[^8]

Active Research Areas

External Links

• [NIA: What Is LATE?](https://www.nia.nih.gov/health/alzheimers-and-dementia/what-limbic-predominant-age-related-tdp-43-encephalopathy-late)
• [Mayo Clinic: LATE](https://www.mayoclinic.org/diseases-conditions/dementia/in-depth/late/art-20534312)
• [ALZFORUM: LATE](https://www.alzforum.org/news/research-news/introducing-late-common-tdp-43-proteinopathy-strikes-after-80)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid-Beta Aggregation](/mechanisms/amyloid-aggregation)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Microglia](/entities/microglia)
• [neuroinflammation](/mechanisms/neuroinflammation)
• [Astrocytes](/entities/astrocytes)
• [Hippocampus](/brain-regions/hippocampus)

Background

The study of Limbic Predominant Age Related Tdp 43 Encephalopathy (Late) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Progression of fiber bundle damage in amnestic Alzheimer's disease and LATE: a 2-year fixel-based study.](https://pubmed.ncbi.nlm.nih.gov/41772333/) (2026 Mar 2) - GeroScience
• [The role of brain MR and FDG-PET in the diagnosis of neurodegenerative disease.](https://pubmed.ncbi.nlm.nih.gov/40903623/) (2026 Mar) - European radiology
• [Elucidation of Molecular Mechanisms of Lipid-Altered Cytotoxicity of TDP-43 Fibrils.](https://pubmed.ncbi.nlm.nih.gov/41609580/) (2026 Feb 18) - ACS chemical neuroscience
• [TRIM32-UBQLN2-p62 axis promotes TDP-43 inclusion formation and amyloid aggregation through shuttle condensates.](https://pubmed.ncbi.nlm.nih.gov/41727138/) (2026 Feb 13) - bioRxiv : the preprint server for biology
• [TDP-43 pathology is linked to motor neuron loss but is independent of stress granules in vivo.](https://pubmed.ncbi.nlm.nih.gov/41727136/) (2026 Feb 13) - bioRxiv : the preprint server for biology

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

References